ArticleThe Pan African medical journal2024
Intravitreal bevacizumab causes rapid regression of disc neovascularization associated with large optic disk melanocytoma: a case report.
Article in The Pan African medical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Optic disk melanocytoma (ODM) is a rare ophthalmic tumor that can present with local compressive effects such as retinal vascular occlusion (RVO) that results in neovascularization of the disk (NVD) and is reportedly challenging to treat. We report the case of a 37-year-old Black African male with a two-year history of painless nonprogressive blur in his right eye vision. Findings on ocular examination include best corrected visual acuity right eye 6/18 and left eye 6/6, right eye relative afferent pupillary defect, and a large dark brown pigmented mass covering the optic disc measuring 4.8 mm x 4.6 mm. NVD was present along the superior disc margin and whitening of the superotemporal retinal vessels. Fluorescein angiography confirmed a superotemporal retinal vascular occlusion with non-perfusion and dye leakage from the NVD. Intravitreal bevacizumab and scatter retinal laser resulted in complete NVD regression within four weeks and no recurrence in 18 months. This case report suggests that earlier treatment with Intravitreal bevacizumab and scatter retinal laser photocoagulation is effective for the regression and stabilization of NVD associated with ODM. Aggressive ODM could be a feature in younger-age Africans. Yearly monitoring is required to detect an increase in ODM size that could suggest malignant transformation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.